23rd Annual Biotech in Europe Forum

Adiso is a clinical-stage biopharmaceutical company dedicated to improving the health of patients suffering from debilitating inflammatory diseases. This dedication is epitomized by our lead clinical candidates, ADS051, an oral gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis; and ADS032, a dual NLRP3/NLRP1 inflammasome inhibitor initially being developed for inflammatory diseases of the lung, additionally ADS024, an oral single strain live biotherapeutic product (LBP) mild-to-moderate ulcerative colitis and prevention of C. difficile recurrence. Adiso has built these development programs upon a rich history of institutional and academic collaboration, including the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia, the University of Edinburgh Centre for Inflammation Research and the University College Cork, Ireland, the APC Microbiome Institute.

AM-Pharma, a private clinical stage biotech company based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa as an enzyme replacement therapy administered sc for the rare disease hypophosphatasia, clinical PoC achieved, the compound can be on the market by 2030 and the market potential exceeds EURO 1B.

First-in-Class Disease-Modifying Therapeutics in Cardiac and Skeletal Muscle Diseases.

Founded in 2018, Azafaros is a clinical-stage biotech company working on building a pipeline of disease-modifying therapeutics to offer new treatment options to patients with lysosomal storage disorders, including GM1 and GM2 Gangliosidoses and Niemann-Pick disease type C.

Immune checkpoint inhibitors (ICIs) has significantly changed the landscape in oncology, but this groundbreaking progress is a reality for only a limited fraction of patients. What about the others? What about the vast majority of non-responders? Domain is the only one company fully dedicated to exploit the unique potential of GPCR in immuno-oncology. Domain Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology to bring solution to patients who do not response to ICI treatment. Backed to 20 years of expertise in GPCR drug discovery and delivery, the company pioneers the huge and unveiled potential of GPCRs in immunosuppression to deliver game changing treatments abled to reverse immunosuppression mediated by the membrane receptors. Its pipeline is made of: • A2a/A2b antagonist (M1069) - small molecule candidate in partnership with Merck KGaA - Phase I ascending dose study ongoing • EP4 receptor antagonist (DT-9081) - small molecule candidate - Phase I ascending dose study dosing ongoing • Anti-CCR8 antibody (DT-7012) - monoclonal antibody candidate - Phase I study to commence by mid-2025 • PAR2 NAM antagonist (DT-9045) - small molecule candidate - Phase I study to commence by mid-2025 The company positions each asset in the right indication, the right subpopulation of patients and with the right combo to reach the optimal benefit and success rate in the clinic and bring solution to cancer patients. Domain exploits a differentiating cross validated approach to identify GPCRs specifically expressed in tumor infiltrates and involved in immunosuppression. Domain is the partner of choice to discover, launch and bring to the clinic immunotherapies to bypass immunosuppression responsible of clinical failure of immune checkpoint inhibitors and turning tumors into non-responding status.

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of neurodegenerative diseases, such as Multiple Sclerosis (MS), Post-COVID (PASC) and Amyotrophic Lateral Sclerosis (ALS).

A public clinical-stage biopharma company developing epigenetics for CNS disorders and oncology/hematology. c.50 highly-qualified professionals located in Barcelona, Boston and San Diego. Listed in Spain, aiming at NASDAQ-listing. Two uncorrelated clinical-stage compounds: vafidemstat (Phase III-ready, CNS) and iadademstat (Phase II, oncology/hematology). Pioneering development of epigenetic drugs in CNS with vafidemstat, a safe LSD1 inhibitor, administered to + 425 subjects. The drug has shown promising results in reducing agitation/aggression in psychiatric patients in a Phase IIa basket trial, and in a global randomized, double blind Phase IIb trial in BPD (PORTICO, final results presented at ECNP-2024). Phase III in agitation/aggression in borderline personality disorder (BPD) in preparation. Vafidemstat is also being investigated for treating negative symptoms of schizophrenia in a randomized, double-blind Phase IIb trial (ongoing trial expansion to additional EU countries). Preparing a new Phase II trial in aggression in patients with ASD, including genetically-defined ASD subpopulations such as Phelan McDermid Syndrome. Iadademstat, a best-in-class LSD1 inhibitor, is in clinical development for AML, solid tumors and hematological disorders. PoC with strong clinical activity in combo with azacitidine in a Phase II in unfit AML patients, and encouraging signals in 2L-ED-SCLC. Highly encouraging data presented at ASH-2025 from ongoing trials in 1L AML (in combo with venetoclax/azacitidine, 100% ORR, 90% CR) and in R/RFlt3mut+ AML (in combo with gilteritinib, 67% CCR at the dose under expansion). Additional trials ongoing in MDS (in combo with azacitidine),1L SCLC (in combo with ICI), and in MPN (in combo with ASTX727). Expanding into hematological indications: sickle cell disease (PhIb trial approved by EMA, recruiting), essential thrombocythemia (PhII in prep).

OSE Immunotherapeutics is a clinical-stage and public biotech company focused on developing and partnering First-In-Class immunotherapies to control the immune system for immuno-oncology and immuno-inflammation. Five clinical assets: • Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company’s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Confirmatory pivotal phase 3 in preparation. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors. • OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia. • OSE-172/BI 765063 (anti-SIRPα monoclonal antibody on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 dose escalation results in monotherapy and in combination, in particular with anti-PD-1 antibody ezabenlimab; international Phase 1b ongoing clinical trial in combination with ezabenlimab alone or with other drugs. • FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); Phase 2 under preparation. • OSE-279 (anti-PD1): ongoing Phase 1/2 in solid tumors or lymphomas. Two innovative Research platform: • BiCKI® platform is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. BiCKI-IL-7 is the most advanced BiCKI® candidate targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO and immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb) is the most advanced candidate generated by the platform, with the potential to resolve chronic inflammation by targeting Neutrophils and inflammatory Macrophages.

Preci aims to bridge the gap between animal testing and the outcome of the clinical trials. Preci provides high-quality services in creation of primary human tissue-based assays. Our projects start with the assembly of the patient cohort, continue towards creation of the living 3D disease model and assay development. In this way, agnostic towards any particular biological technology, estimating only success rate data, we extract the prognosis of drug activity in humans. Our platform is scalable towards 100s of donors in single or multiple indications. All of our work is empowered by the wide clinical network, which ensures ethical collection of samples and patient data, needed to fulfil the particular project.

Teitur Trophics: Advancing Neurodegeneration Treatments Teitur Trophics is a biopharmaceutical company dedicated to developing transformative treatments for neurodegenerative diseases, including Huntington's Disease, Parkinson's Disease, and Frontotemporal Dementia. The company company is founded on pioneering research conducted at Aarhus University, where scientists uncovered a novel pathway that plays a critical role in maintaining neuronal survival and function. This pathway uniquely targets three key pillars of neurodegeneration: improving mitochondrial function, enhancing lysosomal function, and preserving synaptic integrity. By addressing these interconnected mechanisms, we aim to protect and restore the health of neurons, ultimately slowing or even halting disease progression. Our lead program, TT-P34, represents a groundbreaking advance in the field of neurodegeneration. TT-P34 is a first-in-class peptide therapy that has demonstrated potent efficacy in preclinical studies, including its ability to slow or halt disease progression in animal models of Huntington's Disease and Parkinson's Disease. Importantly, the compound is designed with patient convenience in mind, offering a once-weekly subcutaneous injection, reducing treatment burden and improving adherence. With a strong foundation of preclinical data supporting its safety and efficacy, TT-P34 is set to enter first-in-human studies in Q2 2025, where it will initially be tested in healthy volunteers. This milestone marks a significant step toward bringing a much-needed, disease-modifying therapy to patients suffering from devastating neurodegenerative disorders. At Teitur Trophics, we believe that innovation in science is the key to addressing the complex challenges of neurodegeneration. By focusing on a holistic approach to neuronal health and leveraging cutting-edge research, we are committed to developing therapies that not only extend life but also preserve its quality for patients and their families.

Vaccentis AG is a Zurich-based company focused on the biotech and pharmaceutical sector. All research, development and clinical activities are carried out by a highly specialised subsidiary, VCC MEDICAL. VCC MEDICAL DIVISION IS DEVELOPING CLINICALLY PROVEN PRODUCTS, SHOWN TO MAINTAIN REMISSION AND ALLEVIATE DISEASE VCC-001 cancer vaccine Phase III data in Renal Cell Cancer has demonstrated clinical effect and was well tolerated, a disease with few current treatment options VCC-001 cancer vaccine concept has significant potential in colon and pancreatic cancers.

AATec develops novel biopharmaceuticals for major respiratory inflammatory diseases such as COPD, bronchiectasis, asthma, and respiratory infections. The first indication for clinical development will be non-CF bronchiectasis. Our product platform is based on a novel version of alpha-1 antitrypsin for inhalation, a multimodal anti-protease and immuno-modulator with superior therapeutic effects and a new inhaler device. The technology platform has been established and preclinical proof-of-concept has been shown. The first clinical study in non-CF bronchiectasis is planned to start in 2025.

Akribion Genomics develops a revolutionary, genetically-programmable and new therapy class for oncology, using novel nucleases, causing programmable cell depletion via RNA biomarker recognition. The nuclease can target a wide variety of cancer indications defined by genetic make up of patients and can also be applied beyond oncology. The nucleases are protected by a s trong IP position with FTO and the key patent granted in September 2023. The technology had initially been developed within and the company is a spin out of BRAIN Biotech, a stock listed industrial Biotech player that focuses on industrial applications.

AmacaThera is a clinical stage company focused on the commercialization of a hydrogel platform for sustained drug release. AmacaThera's propriety technology can be combined with therapeutic agents to form a product, which will localize the therapeutics to the injection site to improve the duration of action when injected into a tissue. AmacaThera’s hydrogel platform is compatible with a wide range of therapeutics and can sustain release from a few days up to a month. AmacaThera has shown applicability to a wide range of therapeutics from small molecules to growth factors and is seeking investment and collaborations to develop additional applications.

Amarna Therapeutics is pioneering advancements in autoimmune disease treatment through its proprietary Nimvec™ gene delivery platform, which focuses on addressing the root causes of diseases rather than merely alleviating symptoms. The company’s lead product, AM510, is designed to tackle the autoimmune origins of Type 1 Diabetes (T1D), offering the potential to eliminate the need for insulin therapy. This represents a groundbreaking innovation in a €45 billion market expected to nearly double by 2032.To drive this innovation forward, Amarna has secured €8.5 million from existing investors and is seeking an additional €26.5 million to complete its €35 million Series A funding round. These funds will support the advancement of AM510 into clinical trials, marking a significant milestone as the first SV40-based vector to be tested in humans—a development poised to transform global healthcare. The Nimvec™ platform offers notable advantages over adeno-associated virus (AAV) vectors. While both have similar loading capacities, Nimvec candidates are 100 times more potent than AAV. Additionally, Nimvec’s non-immunogenic nature allows for drug redosing, providing a distinct edge in therapeutic applications. We would welcome the opportunity to introduce our novel gene therapy platform and discuss our fundraising plans in greater detail.

Amyl therapeutics develops a breakthrough platform of fusion proteins for the treatment of amyloid mediated diseases: amyloidosis, neurodegenerative diseases and others. The mode of action is unique as we target several proteins through a dual clearing mechanism, with a potential for cure of severe and untreatable diseases.

Atamyo Therapeutics is a clinical-stage biopharma focused on the development of a new generation of effective and safe gene therapies for muscular dystrophies and cardiomyopathies. A spin-off of gene therapy pioneer Genethon, Atamyo leverages unique expertise in AAV-based gene therapy and muscular dystrophies from the Progressive Muscular Dystrophies Laboratory at Genethon. Atamyo has a clinical-stage pipeline with first-in-class vectors which include new capsids, new promoters, and organs-detargeting technologies: - ATA-100 is in phase 1b/2b in LGMD-R9/LGMD2I associated to deficiencies in the protein FKRP. - ATA-200 has received clinical trial clearance for LGMD-R5 related to deficiencies in γ-sarcoglycans, - ATA-300 is in IND-enabling studies and targets LGMD-R1/ LGMD2A or calpainopathy; - The cardiomyopathy programs pursues several targets in Dilated Cardiomyopathies Atamyo’s seasoned management has a unique expertise in developing biotech products from Research to late stage clinical development: - Stephane Degove, its CEO, is a biotech entrepreneur with 25 years’ experience in pharma/biotech and strategy. - Isabelle Richard, PhD, its Chief Scientific Officer, heads the Muscular Dystrophy department at Genethon and a pioneer in the research on gene therapy targeting muscular distrophies. - Dr Sophie Olivier, its Chief Medical Officer, has extensive clinical development experience in large and small pharma organizations and has overseen multiple regulatory interactions with both the FDA and the EMA, particularly in regard to pediatric development and rare diseases. - Catherine Cancian, its Chief Technical Officer, has 25 years CMC development in biologics, including gene therapy. The name of the company is derived from two words: Celtic Atao which means “Always” or “Forever” and Myo which is the Greek root for muscle. Atamyo conveys the spirit of its commitment to improve the life of patients affected by neuromuscular diseases with life-long efficient treatments.

BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform. Biomunex is developing a disruptive biological approach, the MAIT-engagers, that redirect MAIT cells to kill cancer cells, which may become a true game changer in the field of cancer immunotherapy.

Causal mapping of the genome: Unveiling the genes that cause or influence biological effects, traits, or diseases.

Bioxodes SA is a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. The company’s lead asset, BIOX-101, is a first-in-class drug candidate being developed to treat stroke. BIOX-101’s unique dual mechanism of action is the foundation of an innovative pipeline of drug candidates for treatment and prevention of thromboinflammatory diseases. Worldwide, Bioxodes holds both granted and pending patents associated with BIOX-101.

CellProthera is a clinical-stage biotech developing innovative stem cell therapies. Preliminary data from its Phase I/IIb show promising results of its lead product candidate ProtheraCytes®. The therapy aims at repairing damaged heart tissues following a severe myocardial infarction, preempting the deleterious occurrence of heart failure. Its cellular product, based on unique production methods and a protected technology, has the potential to reperfuse and salvage even the deepest layers of the heart through the development of new blood vessels. The company’s technology has been tested in other indications, such as ischemic stroke, with successful preclinical results.

Delta4 is an AI Drug Discovery Biotech Company with a focus on Indication Expansion. By utilizing Hyper-C, a proprietary artificial intelligence powered platform, Delta4's team detects relationships between drugs with a known safety profile and diseases with unprecedented speed.

Engimmune Therapeutics is developing next-generation T cell receptor (TCR)-based therapies to address unmet patient needs in oncology and immune-mediated diseases. We couple high-throughput data generation and artificial intelligence (AI) to accelerate soluble TCR drug development.

GliaPharm's pioneering approach is to stimulate energy utilization in the brain by targeting a type of glial cells called astrocytes, representing an innovative approach for the treatment of neurological and psychiatric disorders.

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Intract is leveraging it's oral biologics delivery platform to create a best-in-class pipeline of orally delivered antibody medicines in immuno-inflamamtory indications. Lead asset is an oral IL12/23 inhibitor mAb currently in preclinical for treatment of moderate to severe ulcerative colitis.

leon-nanodrugs GmbH (“LEON”) is a pharmatech company specializing in the development and marketing of devices for the encapsulation of genetic material and other active substances into nanodrug carriers, such as lipid nanoparticles (LNPs).

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer. Technology Immuno-Modulatory Alpha Neutrophil progenitors (IMANs) produced from iPSCs or HSCs using our N-LIfT Platform Stage Pre-clinical work completing, IND filing Focus Solid Tumours with high unmet medical need, starting with SCC-NSCLC, PDAC, HNSCC, UCC Patents 2016 Filing Granted, 6 Patents with FTO Current Raise £25m+ Series A. Pharma license discussions underway. Recent Achievements - Successful production from iPSCs and GMP ready production from HSCs at 10L - Increase T-cell and NK cancer killing 250% in Lab-on-chip tumour model - Unmodified IMANs shows comprehensive solid tumour organoid killing (superior to Keytruda & Abraxane) in NSCLC, PDAC - HER-2 CAR IMANs increase cancer cell killing x5 over the already potent unmodified LIfT IMANs have preclinical validation of all of the characteristics required to overcome the challenges to achieving sustained remission in solid tumours.

On/Off Therapeutics is a start-up company at IND-enabling stage, developing a breakthrough technology published in Nature Biotechnology, which enables the expression of genes to be controlled in vivo over time. The technology, called Nutrireg®, is based on the activation of a proprietary artificial promoter by a specific, also proprietary, dietary supplement. This technology enables the on-demand expression of a transgene previously introduced into the organism (via a viral or non-viral vector), without the use of any potentially toxic activator. It is thus possible to control in situ the production of an mRNA (and therefore of a peptide or protein), or of an siRNA or shRNA, very rapidly and in a totally reversible way, with no leakage. A Phase I clinical trial in healthy volunteers showed that Nutrireg® can be activated and deactivated in 2-3 hours. This technology has therefore a wide range of applications, including in situ biosynthesis of therapeutic peptides with very short half-lives, making them difficult to administer by the iv route, or of therapeutic peptides whose 24-hour in vivo biosynthesis after transfection by gene therapy could be deleterious. Furthermore, preliminary results have shown that controlled activation of certain transgenes can be very useful in cell therapy applications to activate or deactivate certain functions (CAR-T, CAR-NK, etc.). Our strategy is dual: (i) to develop as clinical proof of concept a first product (metastatic colorectal cancer with liver metastases), and (ii) to conduct an active business-development activity with pharmaceutical companies whose candidate-drugs (peptides or nucleic acids) would benefit from our technology. The Sachs Biotech Forum is the first event in our road show intended to meet investors and representatives from pharma companies scouting for breakthrough technologies.

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line). PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised close to €61M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth €108M, plus tiered royalties on net sales in Asia.

PerioTrap is an emerging Biotech company developing novel microbiome-based treatments in oral care. We focus on Pathoblocker approaches that solely reduce virulence to harness efficacy while minimizing bacterial resistance. Our goal is to prevent current and future oral care gaps with more efficient products, specifically in periodontology.

ProVascTec’s mission is to positively impact the lives of patients suffering from cardiovascular complications. ProVascTec is a preclinical stage device-driven cell therapy company, leveraging the paracrine mechanism of stem cells to induce the growth of a novel vascular system, creating a natural bypass around arterial occlusions in the peripheral vascular system, specifically below the knee. Our investigational off-the-shelf stem cells are combined with a proprietary land patent-protected local delivery system, suitable for integration into well established percutaneous delivery procedures.

Resistell AG is a clinical stage company developing the world’s fastest Antibiotic Susceptibility Testing (AST) Platform. Resistell has a CE IVD certified AST in bloodstream infections (BSI) with a time-to-result of 4 hours, tested on 260 patients in two clinical studies across three hospitals (Lausanne, Switzerland; Madrid, Spain; and Innsbruck, Austria). The method shows over 95% accuracy with the gold standard for AST. The 2nd generation device and pre-clinical data enabling an ultra-rapid AST of only 2 hours are already available. In addition to the diagnostic product, Resistell offers a globally certified research device and disposable kits for exploring new applications that we have recently launched on the market. Resistell AST is based on a disruptive, proprietary nanomotion technology platform for measuring induced metabolic changes in living cells combined with machine learning for the development of classification algorithms. The technology is developed in-house by a cross-functional team (30 FTE) of microbiologists, engineers, and data scientists. The company is ISO 13485 certified.

SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. The company is developing a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital-backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma, an indication with high unmet medical need.

TOLREMO therapeutics’ mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound, TT125-802, is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.

WMT develops small molecule drugs to treat late stage solid cancers. We have evolved a drug candidate, B-306, with decent activity in various xenograft and syngeneic tumor models. B-306 induces the Intracellular Stress Response (ISR) which results in a cellular lockdown of protein translation and metabolism. This changes the tumor microenvironment and has the potential to break resistance of late stage solid cancers against classical chemotherapy as well as the chance to improve the efficacy of immunotherapies.

Ymmunobio (YB) is a Swiss preclinical stage oncology biotech company focused on fighting gastro-intestinal cancers. YB is developing novel class and first in class antibodies. The first compound, a novel class of CEACAM1/5 antibodies (YB-200) increases the efficiency of the immune response in clearing cancer cells including an increase in anti-tumor immunity. The second, an NPTXR antibody (YB-800) is a first in class antibody binding on NPTXR-positive cancer cells and not affecting healthy tissue. The YB-800/NPTXR conjugate gets internalized and ADC development is ongoing. Ymmunobio has raised CHF 1.3 Mio to date by founders and private individuals and is now actively pursuing capital investment of CHF 8 Mio to move the development of the lead compound forward to IND approval stage. YB has assembled a team of experts in oncology drug development and renowned scientific leaders in the field of CEACAM & NPTXR research.

Adoram Therapeutics, a University of Geneva spin-off, is developing next-generation (allosteric) small molecule drugs, which are safer and more effective than conventional (orthosteric) small molecules. We have developed an allosteric screening platform to efficiently identify positive or negative modulators of GPCR drug targets. We are securing investments to progress two preclinical stage assets towards human trials, and to expand our pipeline.

Allogenica is a Lyon-based biotechnology company specialized in the development of an emerging class of cancer therapy, called CAR-T cells (Chimeric Antigen Receptor T-cells). Allogenica has developed a bioproduction platform that relies on the manipulation of hematopoietic stem cells and their derivatives with the aim of developing allogenic "off-the-shelf" CAR-T cells. Allogenica will offer the next-generation cancer treatment ready to use, at low cost and safer than current treatments, in order to treat all patients who need it.

AtG is an early-stage pre-clinical biotech company with HQ in Barcelona, Spain, established in 2022 as a spin-off of two leading cancer centers in the country. AtG focuses on Overcoming Tumor Adaptation, which is critical to advance in our fight against cancer, as this is a dynamic disease. Our approach is to develop inhibitors against adaptation vulnerabilities coupled with patient selectors that will be key in addressing this dynamism. AtG has a Target Discovery Platform (TACTIC - Tumor Adaptation Target Identification) that has allowed us to generate multiple targets of interest to date, including TA-1, the focus of our current development efforts. TA-1 is a pro-tumor enzyme that has been identified as a resistant mechanism to anti-angiogenic therapy, a very large established market confirmed to stay by top key opinion leaders that have reviewed the AtG opportunity.  However, TA-1 has also shown to be over-expressed in many untreated tumor types, hence the opportunity of making an impact with an inhibitor against this target is very large. We are currently developing a first in class intracellular inhibitor against TA-1, aiming to have a pre-clinical candidate selected by end of 2024.

CaSRevolution identified a novel upstream therapeutic target for a disease-modifying approach against Alzheimer’s disease: in fact, pharmacological inhibition and genetic manipulation of its new target - which is promising also because it can be modulated with a small molecule - prevent neurodegeneration in disease-relevant in vitro & in vivo models. The management team and the board of directors have broad experience in company creation & successful exits, neurodegeneration, and drug development. It plans to develop First-in-Class compound(s) to treat early-stage AD, MCI, and dementia due to AD. Therefore, it designed a capital-efficient lead-to-candidate drug discovery plan to be ready for an Investigational New Drug (IND) application on the best candidate within 3 years.

FimmCyte is a women’s health company with the vision to create tailored women’s health therapeutics to drive equality and prosperity. FimmCyte’s lead program, FMC2, is a first-in-class disease-modifying treatment for endometriosis, a painful and debilitating condition that affects one in every ten women.

InCephalo was founded in 2021, in Basel, Switzerland, as a UZH spinoff focusing on new therapies for disorders in the CNS. At InCephalo Therapeutics AG, we aim to add brain cancer to the list of curable diseases. We believe that potent immunostimulation, contained in the tumour microenvironment, needs to become a crucial part of today's and future therapeutic interventions. For this, we develop proprietary compartment-locked cytokine therapies with high local tissue retention and fast systemic degradation for a maximised therapeutic index. Despite our project's mature and ambitious nature, we are convinced it could disrupt today’s treatment practices for brain cancer patients. Additionally, our proprietary compartment-locked technology, which retains locally applied biologics in the brain, can be expanded into many other CNS diseases. Therefore opening the door for many more therapeutic solutions in the CNS space.

iPSirius SAS - Targeting Cancer Stem Cells with iPS cell-based therapeutic vaccine IPVAC 1.0. iPSirius SAS is an immuno-oncology firm focused on developing IPVAC 1.0, a novel therapeutic cancer vaccine. Leveraging the antigenic overlap between induced pluripotent stem cells (iPSCs) and cancer stem cells (CSCs), iPSirius aims to combat relapse and metastatic progression in cancer patients. The company, a spinout from Inserm and Saclay University In Paris, is at the forefront of utilizing iPSCs as a delivery system for cancer targets. By training the immune response on CSCs, iPSirius strives to overcome the limitations of current therapies in combating metastases and the emergence of resistance. iPSirius is dedicated to revolutionizing cancer treatment through the development of IPVAC 1.0. The company's initial focus is on non-small-cell lung cancer (NSCLC), where IPVAC has the potential to break up metastatic dissemination. With promising results in animal studies and the inclusion of multiple antigens, IPVAC shows promise for addressing various cancer types. iPSirius has received grant funding USD$2.4M, mainly from the European Innovation Council but also French Private Investment Bank BPI France. Additional tranches of USD$2M or more available subject to clinical milestones being reached. The company is actively seeking series A funding to advance IPVAC 1.0 into clinical trials. With a commitment to innovation and improving patient outcomes, iPSirius aims to bring transformative therapies to the field of cancer treatment. iPSirius has built up an extensive patent portfolio around IPVAC 1.0, and is interested in talking with cell therapy companies considering adding IPVAC 1.0 to their clinical program as a de-risking measure against the production of more complex living cell therapy products.

LaRive Bio AG, a Swiss-based organization, is dedicated to accelerating the development of therapeutic solutions for some of the most challenging chronic conditions. Our business model is centered on a platform for acquiring, developing and divesting molecules from and to biotech companies. By utilizing our core drug and business development expertise, we partner with innovative biotech groups to lead promising candidates through Phase I / II and potentially Phase III studies and build a business plan for successful divestment or out-licensing. Priority is given to commercially attractive drug candidates that qualify for accelerated regulatory pathways. Led by a highly experienced team with a proven track record in biopharmaceutical and business development sectors, LaRive Bio initiates a CHF 10 million raise to launch a Phase I trial for a novel molecule for Multiple Sclerosis.

Modiblast pursues a novel in vivo cell reprogramming approach to treat hematological malignancies and other cancers. Our proprietary strategy aims to drive leukemia-specific innate & adaptive immune responses and establish memory cells. With our lead pipeline program progressing towards a first clinical trial in AML, we are in the process of raising a seed round. Our long-term vision is to establish a cancer backbone therapy capable of prolonging phases in remission. We aim to enable patients to self-administer this novel drug combination at home, drastically improving their quality of life.

Mysthera Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a first-in-class therapeutic approach, Mysthera plans to reshape the treatment landscape for autoimmune disease. PIM kinase inhibition uniquely and selectively modulates immune cell function in multiple lineages associated with complex disease. The company’s pipeline includes pre-clinical stage, PIM kinase inhibitors in-licensed from Inflection Biosciences Ltd.

We are a startup (creation 2017) from Strasbourg developing a proprietary personalized and powerful immunotherapy platform based on the disruptive technology of Synthetic DNA and advanced algorithms . We aim to treat patients suffering form hard to treat cancer in a shortened timeframe (8 weeks) .We have strong POC and secured GMP supply chain. We aim for First in man clinical trial end of 2023.

On/Off Therapeutics is a start-up company at IND-enabling stage, developing a breakthrough technology published in Nature Biotechnology, which enables the expression of genes to be controlled in vivo over time. The technology, called Nutrireg®, is based on the activation of a proprietary artificial promoter by a specific, also proprietary, dietary supplement. This technology enables the on-demand expression of a transgene previously introduced into the organism (via a viral or non-viral vector), without the use of any potentially toxic activator. It is thus possible to control in situ the production of an mRNA (and therefore of a peptide or protein), or of an siRNA or shRNA, very rapidly and in a totally reversible way, with no leakage. A Phase I clinical trial in healthy volunteers showed that Nutrireg® can be activated and deactivated in 2-3 hours. This technology has therefore a wide range of applications, including in situ biosynthesis of therapeutic peptides with very short half-lives, making them difficult to administer by the iv route, or of therapeutic peptides whose 24-hour in vivo biosynthesis after transfection by gene therapy could be deleterious. Furthermore, preliminary results have shown that controlled activation of certain transgenes can be very useful in cell therapy applications to activate or deactivate certain functions (CAR-T, CAR-NK, etc.). Our strategy is dual: (i) to develop as clinical proof of concept a first product (metastatic colorectal cancer with liver metastases), and (ii) to conduct an active business-development activity with pharmaceutical companies whose candidate-drugs (peptides or nucleic acids) would benefit from our technology. The Sachs Biotech Forum is the first event in our road show intended to meet investors and representatives from pharma companies scouting for breakthrough technologies.

PRAMOMOLECULAR is an early-stage biopharmaceutical company developing anti-cancer drugs based on proprietary self-delivering siRNAs. Our self-delivering siRNAs are particularly good at crossing the cell membrane of non-hepatic tissues such as lung, heart, pancreas, or colon in vivo. This enables efficient gene silencing in these target tissues. PRAMOMOLECULAR is currently working on lead optimization of drug candidates against cancers in target tissues caused by oncogenic KRAS mutations. We also offer the delivery technology to other developers of therapeutic oligonucleotides for selected applications.

Reconnect Labs is a Swiss, clinical stage biotech company developing rapid-acting precision therapeutics for interventional precision psychiatry with the potential to transform the treatment landscape for substance use disorders, post-partum depression, PTSD, and insomnia.

StemSight is a pre-clinical stage biopharma company developing proprietary hypoimmune, allogeneic cell-based therapies derived from human induced pluripotent stem cells (iPSCs) to treat blindness. Our technology platform using proprietary differentiation methods and biomaterial carriers have spun out two different products. We showcase our technology in the rare disease limbal stem cell deficiency, a high-reimbursement-potential unmet need, while looking to expand the platform to more major indications.

Even today, one of the most critical issues is the capability to target all tumour cells present within a cancer. The proprietary and patented platform that TheraOnco has developed has the potential to bridge this gap. TheraOnco was co-founded in 2022 by Dr. Sam Dukan, a serial entrepreneur / visionary inventor, and Didier Noel, experienced in technology transfer and startup financing. After preliminary validation of its disruptive cell labelling-mediated platform targeting cancer, TheraOnco revealed positive preclinical toxicity and efficacy results in animals for its leading candidate metabolite analogue. Our proprietary platform is based on localizing preferentially bio-orthogonal function (-N3 function) in macromolecules present in tumour cells via internal assimilation and metabolization of a non-toxic clickable natural pentose analogue, exclusively through the pentose phosphate pathway (over-expressed in almost all tumour cells, as a tumour hallmark). Using this process, we may render all tumour cells “identical” to whatever they were before the assimilation of our metabolic analogues. Using bio-orthogonal click chemistry, we then covalently link these to all kinds of clickable molecules (fluorochrome, antitumour agents, antibodies, liposomes….) allowing us to preferentially localize or destroy tumour cells. Today, we have (i) substantial proof of concept of our platform in vitro, with more than 30 tumour cell lines preferentially labeled, and (ii) preliminary proof of concept for pancreatic and lung (NSCLC) cancer in animals. In summary, our proprietary platform allows artificial antigens to be inserted onto all tumour cell surfaces, providing enhanced efficacity of all antitumour agents and decreased side effects. Although, as for ADC, there is a local concentration of antitumour agent, our approach is radically different since it is agnostic of the type of cancer and is much cheaper (with regards to development time and cost). More importantly, within a tumour, all tumour cells will be targeted.

Brenus Pharma is a French clinical-stage biotech company developing an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response against evolving tumor cells. www.brenus-pharma.com